Sanofi THOR-707 and Merck Keytruda to be evaluated for cancer combotherapy

THOR-707 demonstrated in preclinical studies the ability to induce the expansion of CD8+T-cells resulting in anti-tumor effects both as single agent as well as in combination with an anti-PD1 mAb.